Allergan seeks to fend off a takeover by Valeant

Valeant Pharmaceuticals, the Canadian company that took over Bausch & Lomb a year ago for $8.7 billion, has proposed to take over Allergan as well, at a price that would reportedly value the company at $45.6 billion. It's a very high price for Allergan, which made a net profit of ...

You need to register to continue reading this article

Already subscribe to Eyewear intelligence? Sign in here

Register to continue reading

By registering today you will have access to:

  • 3 industry news articles per month

For full access and to receive in-depth news, analysis and more, become a member today

For more content and resources become a member? View our membership packages.